Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2016; 22(43): 9515-9524
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9515
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9515
Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK
Ya-Jing Feng, Yong-Yu Li, Xu-Hong Lin, Kun Li, Ming-Hua Cao, Department of Pathophysiology, Tongji University School of Medicine, Shanghai 200092, China,
Ya-Jing Feng, Department of Center ICU, East Hospital, Tongji University School of Medicine, Shanghai 200120, China
Author contributions: Li YY designed the project; Feng YJ performed the experiments and analyzed the data; Lin XH, Li K and Cao MH contributed to performing the experiments and in data analysis; Feng YJ and Li YY wrote the paper.
Supported by the National Natural Science Foundation of China , No. 81400581 (to Feng YJ) and No. 81270477 (to Li YY) .
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Department of Pathophysiology, Tongji University School of Medicine, China.
Institutional animal care and use committee statement: All experiments involving animals were reviewed and approved by the Animal Care and Use Committee of Tongji University (IACUC No. 2008-001).
Conflict-of-interest statement: We declare that the authors of this article do not have any conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yong-Yu Li, MD, Department of Pathophysiology, Tongji University School of Medicine, 1239 Siping Road, Shanghai 200092, China. liyongyu@tongji.edu.cn
Telephone: +86-21-65981021 Fax: +86-21-65987071
Received: June 22, 2016
Peer-review started: June 24, 2016
First decision: August 22, 2016
Revised: September 4, 2016
Accepted: September 28, 2016
Article in press: September 28, 2016
Published online: November 21, 2016
Processing time: 148 Days and 16.6 Hours
Peer-review started: June 24, 2016
First decision: August 22, 2016
Revised: September 4, 2016
Accepted: September 28, 2016
Article in press: September 28, 2016
Published online: November 21, 2016
Processing time: 148 Days and 16.6 Hours
Core Tip
Core tip: Inflammatory bowel disease demands more effective therapies, and cannabinoids are beneficial in alleviating inflammation in some diseases. In this study, we reported the anti-inflammatory effect and protective role of WIN55-212-2, an agonist of cannabinoid receptors, on the mice with dextran sulfate sodium-induced experimental colitis, and revealed that this agent exerts its action at least partially by inhibiting p38 mitogen-activated protein kinase.